Indications

Invasive Aspergillosis (see Aspergillus)

• FDA-Approved in 3/15
• May Be Used as an Alternative to Voriconazole (see Voriconazole)

Mucormycosis (see Mucormycosis)

• FDA-Approved in 3/15
• May Be Used as an Alternative to Posaconazole (see Posaconazole)

---

Pharmacology

Isavuconazole is a Triazole Anti-Fungal

• Isavuconazole is Formulated as a Pro-Drug (Isavuconazonium Sulfate)
  • Mechanism: inhibition of lanosterol 14 alpha-demethylase (enzyme which converts lanosterol to ergosterol by demethylation) -> disrupted fungal cell membrane structure
  • Mammalian Cells are Resistant to Demethylation Inhibition by Azoles, Therefore, this Effect is Specific to Fungi

Metabolism

• xxx

---

Administration

• PO: xx
• IV: xx

Dose Adjustment

• Hepatic
• Renal

Use in Pregnancy (see Pregnancy)

• xxx

Use in Lactation

• xx

---

Adverse Effects

Hepatic Adverse Effects

• Elevated Liver Function Tests (LFT’s) (see Elevated Liver Function Tests and Drug-Induced Hepatotoxicity)
  • Epidemiology
    • Hepatoxicity is a Class Effect Common to Azole Antifungals (see Azole Antifungals)
    • Incidence of Elevated LFT’s is Less than that of Voriconazole

Other Adverse Effects

• xxx
• xxx

---

References

• Isavuconazole: A New Option for the Management of Invasive Fungal Infections. Ann Pharmacother. 2015 Jul;49(7):825-42. doi: 10.1177/1060028015581679. Epub 2015 May 4 [MEDLINE]